1. Home
  2. CINGW vs SRPT Comparison

CINGW vs SRPT Comparison

Compare CINGW & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • SRPT
  • Stock Information
  • Founded
  • CINGW N/A
  • SRPT 1980
  • Country
  • CINGW United States
  • SRPT United States
  • Employees
  • CINGW 13
  • SRPT N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CINGW Health Care
  • SRPT Health Care
  • Exchange
  • CINGW Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • CINGW N/A
  • SRPT N/A
  • IPO Year
  • CINGW 2021
  • SRPT 1997
  • Fundamental
  • Price
  • CINGW $0.04
  • SRPT $106.28
  • Analyst Decision
  • CINGW
  • SRPT Buy
  • Analyst Count
  • CINGW 0
  • SRPT 22
  • Target Price
  • CINGW N/A
  • SRPT $174.64
  • AVG Volume (30 Days)
  • CINGW N/A
  • SRPT 809.5K
  • Earning Date
  • CINGW N/A
  • SRPT 02-26-2025
  • Dividend Yield
  • CINGW N/A
  • SRPT N/A
  • EPS Growth
  • CINGW N/A
  • SRPT N/A
  • EPS
  • CINGW N/A
  • SRPT 1.22
  • Revenue
  • CINGW N/A
  • SRPT $1,640,348,000.00
  • Revenue This Year
  • CINGW N/A
  • SRPT $53.06
  • Revenue Next Year
  • CINGW N/A
  • SRPT $68.79
  • P/E Ratio
  • CINGW N/A
  • SRPT $87.13
  • Revenue Growth
  • CINGW N/A
  • SRPT 48.45
  • 52 Week Low
  • CINGW N/A
  • SRPT $101.15
  • 52 Week High
  • CINGW N/A
  • SRPT $173.25
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • SRPT 35.36
  • Support Level
  • CINGW N/A
  • SRPT $101.15
  • Resistance Level
  • CINGW N/A
  • SRPT $111.21
  • Average True Range (ATR)
  • CINGW 0.00
  • SRPT 3.61
  • MACD
  • CINGW 0.00
  • SRPT -0.37
  • Stochastic Oscillator
  • CINGW 0.00
  • SRPT 27.14

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: